化学
体内
环氧化物水解酶2
生物化学
活动站点
水解酶
磷酸酶
酶
酸性磷酸酶
环氧化物水解酶
立体化学
生物
微粒体
生物技术
作者
Jan S. Kramer,Stefano Woltersdorf,Thomas Duflot,Kerstin Hiesinger,Felix F. Lillich,Felix Knöll,Sandra K. Wittmann,Franca‐Maria Klingler,Steffen Brunst,A. Chaikuad,Christophe H.P. Morisseau,Bruce D. Hammock,Carola Buccellati,Angelo Sala,G. Enrico Rovati,Matthieu Leuillier,Sylvain Fraineau,Julie Rondeaux,Víctor Hernández‐Olmos,Jan Heering
标识
DOI:10.1021/acs.jmedchem.9b00445
摘要
The emerging pharmacological target soluble epoxide hydrolase (sEH) is a bifunctional enzyme exhibiting two different catalytic activities that are located in two distinct domains. Although the physiological role of the C-terminal hydrolase domain is well-investigated, little is known about its phosphatase activity, located in the N-terminal phosphatase domain of sEH (sEH-P). Herein we report the discovery and optimization of the first inhibitor of human and rat sEH-P that is applicable in vivo. X-ray structure analysis of the sEH phosphatase domain complexed with an inhibitor provides insights in the molecular basis of small-molecule sEH-P inhibition and helps to rationalize the structure–activity relationships. 4-(4-(3,4-Dichlorophenyl)-5-phenyloxazol-2-yl)butanoic acid ( 22b, SWE101) has an excellent pharmacokinetic and pharmacodynamic profile in rats and enables the investigation of the physiological and pathophysiological role of sEH-P in vivo.
科研通智能强力驱动
Strongly Powered by AbleSci AI